274 related articles for article (PubMed ID: 29669171)
1. Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma.
Impagnatiello F; Bastia E; Almirante N; Brambilla S; Duquesroix B; Kothe AC; Bergamini MVW
Br J Pharmacol; 2019 Apr; 176(8):1079-1089. PubMed ID: 29669171
[TBL] [Abstract][Full Text] [Related]
2. Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension.
Fingeret M; Gaddie IB; Bloomenstein M
Clin Exp Optom; 2019 Nov; 102(6):541-550. PubMed ID: 30614563
[TBL] [Abstract][Full Text] [Related]
3. FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma.
Sharif NA; Odani-Kawabata N; Lu F; Pinchuk L
Exp Eye Res; 2023 Apr; 229():109415. PubMed ID: 36803996
[TBL] [Abstract][Full Text] [Related]
4. The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies.
Cavet ME; DeCory HH
J Ocul Pharmacol Ther; 2018; 34(1-2):52-60. PubMed ID: 28783422
[TBL] [Abstract][Full Text] [Related]
5. Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension.
Kaufman PL
Expert Opin Pharmacother; 2017 Mar; 18(4):433-444. PubMed ID: 28234563
[TBL] [Abstract][Full Text] [Related]
6. Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension.
Hoy SM
Drugs; 2018 May; 78(7):773-780. PubMed ID: 29761382
[TBL] [Abstract][Full Text] [Related]
7. A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs.
Impagnatiello F; Borghi V; Gale DC; Batugo M; Guzzetta M; Brambilla S; Carreiro ST; Chong WK; Prasanna G; Chiroli V; Ongini E; Krauss AH
Exp Eye Res; 2011 Sep; 93(3):243-9. PubMed ID: 21356209
[TBL] [Abstract][Full Text] [Related]
8. A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma.
Borghi V; Bastia E; Guzzetta M; Chiroli V; Toris CB; Batugo MR; Carreiro ST; Chong WK; Gale DC; Kucera DJ; Jia L; Prasanna G; Ongini E; Krauss AH; Impagnatiello F
J Ocul Pharmacol Ther; 2010 Apr; 26(2):125-32. PubMed ID: 20415621
[TBL] [Abstract][Full Text] [Related]
9. Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma.
Klimko PG; Sharif NA
Br J Pharmacol; 2019 Apr; 176(8):1051-1058. PubMed ID: 29665040
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma.
Wang Y; Liao Y; Nie X
Clinics (Sao Paulo); 2020; 75():e1874. PubMed ID: 33263632
[TBL] [Abstract][Full Text] [Related]
11. Prostaglandin FP receptor agonists in the treatment of glaucoma and ocular hypertension: a literature review.
Moshegov S; Kerr NM
Expert Opin Investig Drugs; 2023; 32(11):1017-1023. PubMed ID: 37929314
[TBL] [Abstract][Full Text] [Related]
12. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.
Schachar RA; Raber S; Courtney R; Zhang M
Curr Eye Res; 2011 Sep; 36(9):809-17. PubMed ID: 21851167
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy.
Denis P; Lafuma A; Khoshnood B; Mimaud V; Berdeaux G
Curr Med Res Opin; 2007 Mar; 23(3):601-8. PubMed ID: 17355741
[TBL] [Abstract][Full Text] [Related]
14. Intraocular Pressure-Lowering Activity of NCX 470, a Novel Nitric Oxide-Donating Bimatoprost in Preclinical Models.
Impagnatiello F; Toris CB; Batugo M; Prasanna G; Borghi V; Bastia E; Ongini E; Krauss AH
Invest Ophthalmol Vis Sci; 2015 Oct; 56(11):6558-64. PubMed ID: 26457541
[TBL] [Abstract][Full Text] [Related]
15. Currently available prostanoids for the treatment of glaucoma and ocular hypertension: A review.
Benitez B; Anter AM; Arcuri J; Bhattacharya SK
Curr Opin Pharmacol; 2024 Feb; 74():102424. PubMed ID: 38160646
[TBL] [Abstract][Full Text] [Related]
16. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
Krauss AH; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WK; Carreiro ST; Ongini E
Exp Eye Res; 2011 Sep; 93(3):250-5. PubMed ID: 21396362
[TBL] [Abstract][Full Text] [Related]
17. Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
Aihara M; Ropo A; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams N
Jpn J Ophthalmol; 2020 Jul; 64(4):398-406. PubMed ID: 32572719
[TBL] [Abstract][Full Text] [Related]
18. Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis.
Harasymowycz P; Royer C; Cui AX; Barbeau M; Jobin-Gervais K; Mathurin K; Lachaine J; Beauchemin C
Br J Ophthalmol; 2022 May; 106(5):640-647. PubMed ID: 33397657
[TBL] [Abstract][Full Text] [Related]
19. Latanoprost : an update of its use in glaucoma and ocular hypertension.
Perry CM; McGavin JK; Culy CR; Ibbotson T
Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
[TBL] [Abstract][Full Text] [Related]
20. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.
Weinreb RN; Scassellati Sforzolini B; Vittitow J; Liebmann J
Ophthalmology; 2016 May; 123(5):965-73. PubMed ID: 26875002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
